Corcept Therapeutics Inc (CORT): G Leonard Jr Baker , director of Corcept Therapeutics Inc purchased 100,000 shares on May 6, 2016. The Insider buying transaction was reported by the company on May 10, 2016 to the Securities and Exchange Commission. The shares were purchased at $4.89 per share for a total value of $487,894.66 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jan 6, 2016, James N Wilson (director) sold 1,188 shares at $2.45 per share price.On Dec 11, 2015, Daniel Bradbury (director) sold 20,000 shares at $4.85 per share price.Also, On Nov 3, 2015, Steven Lo (VP Commercial Operations) sold 12,500 shares at $4.00 per share price.On Jul 9, 2015, David L Mahoney (director) sold 33,828 shares at $5.74 per share price.
Shares of Corcept Therapeutics Incorporated (CORT) ended Friday, May 6, 2016 session in red amid volatile trading. The shares closed down -0.04 points or -0.83% at $4.78 with 1,46,342 shares getting traded. Post opening the session at $4.77, the shares hit an intraday low of $4.69 and an intraday high of $4.87 and the price vacillated in this range throughout the day. The company has a market cap of $525 M and the number of outstanding shares has been calculated to be 10,97,96,626 shares. The 52-week high of Corcept Therapeutics Incorporated is $7.6662 and the 52-week low is $3.22.
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery development and commercialization of drugs for the treatment of severe metabolic psychiatric and oncologic disorders. The Company’s focus is on those disorders that are associated with a steroid hormone cortisol. Elevated levels and abnormal release patterns of cortisol have been implicated in a range of human disorders. It is developing mifepristone a potent glucocorticoid receptor (GR) antagonist that modulates the activity of cortisol for the treatment of a number of severe metabolic psychiatric and oncologic disorders. The Company also discovered three series of selective GR antagonists. As of December 31 2014 it had commenced enrollment in a Phase I clinical study with CORT125134. The Company has completed Phase I trials of CORT108297 for the treatment of central nervous system disorders. The Company’s product Korlym contains 300 milligram mifepristone for the treatment of hyperglycemia.